Immunome financials
$21.89+0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $4.0M | $2.9M | $2.7M | $2.9M | $2.4M | $1.0M | $3.8M | $3.6M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $4.0M | $2.9M | $2.7M | $2.9M | $2.4M | -$110.9M | -$77.0M | $3.6M |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −10779.9% | −2011.9% | 100.0% |
| Operating income | -$78.1M | -$59.3M | -$72.9M | -$60.1M | -$46.5M | -$44.6M | -$83.0M | -$50.5M | -$40.0M | -$132.3M | -$94.7M | -$4.6M |
| Net income | -$73.1M | -$53.8M | -$69.9M | -$57.5M | -$43.4M | -$41.7M | -$80.2M | -$47.1M | -$36.1M | -$129.5M | -$92.6M | -$4.3M |
| Net margin | — | — | — | — | −1080.9% | −1425.2% | −2930.9% | −1618.6% | −1528.0% | −12584.3% | −2421.2% | −121.9% |
| Diluted EPS | $-0.65 | $-0.48 | $-0.74 | $-0.65 | $-0.50 | $-0.52 | $-1.28 | $-0.78 | $-0.60 | $-2.51 | $-2.16 | $-0.36 |
| EBITDA | -$77.2M | -$58.7M | -$72.2M | -$59.5M | -$45.8M | -$44.0M | -$82.5M | -$50.1M | -$39.5M | -$132.1M | -$94.5M | -$4.5M |
| Operating cash flow | -$61.7M | -$58.6M | -$48.0M | -$40.5M | -$49.4M | -$53.1M | -$42.1M | -$34.2M | -$23.4M | -$11.2M | -$17.5M | -$10.3M |
| Free cash flow | -$63.9M | -$61.6M | -$52.0M | -$41.6M | -$50.3M | -$56.7M | -$43.2M | -$35.7M | -$56.1M | -$48.4M | -$17.8M | -$10.3M |
| Diluted shares | 113.3M | 113.1M | 95.0M | 88.0M | 87.0M | 79.4M | 62.9M | 60.2M | 59.9M | 51.5M | 42.8M | 12.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $217.7M | $582.7M | $653.5M | $272.6M | $143.9M | $257.6M |
| Short-term investments | $302.3M | $0.00 | $0.00 | $0.00 | $124.2M | $59.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $565.4M | $619.8M | $683.2M | $299.4M | $296.3M | $342.7M |
| Total liabilities | $40.3M | $31.1M | $48.8M | $35.5M | $27.0M | $35.6M |
| Shareholders' equity | $525.1M | $588.7M | $634.3M | $263.9M | $269.3M | $307.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology